4 results match your criteria: "WHO Collaborating Center for Frailty[Affiliation]"
Association between inflammatory biomarkers and the cognitive response to a multidomain intervention: secondary longitudinal analyses from the MAPT study.
Geroscience
January 2025
Gerontopole, Clinical and Geroscience Research, Toulouse University Hospital, WHO Collaborating Center for Frailty, and Geriatric Training, Toulouse, France.
The aim of this study is to evaluate the association of systemic inflammation measured by plasma biomarkers with the change in cognitive function among participants from the Multidomain Alzheimer Preventive Trial (MAPT) exposed to the multidomain intervention (MI). Secondary analysis of the MAPT longitudinal data. MAPT is a randomized, placebo-controlled trial with 3 interventional groups (omega-3 only, MI only, omega-3 plus MI) and a control group.
View Article and Find Full Text PDFImplementing the WHO ICOPE program in clinical practice: three years of lessons from monitoring 27,082 participants using the ICOPE Monitor digital tool.
J Gerontol A Biol Sci Med Sci
November 2024
IHU HealthAge & WHO Collaborating Center for Frailty, Clinical & Geroscience Research, and Geriatric Training, Toulouse University Hospital, France.
Background: To describe the implementation of the ICOPE program in France using digital tool in order to: 1) describe the characteristics of people completing the screener, identifying differences across assessors (Health Care Professionals (HCP), non-HCPs or self-assessment) 2) describe the characteristics of follow-up and assessments for people with abnormal screening test 3) describe the recommendations in the intervention care plans for people with a decline in intrinsic capacity (IC).
Methods: A descriptive study, presenting the results at initial screening, as well as at assessment when needed; and the recommendations issued during Step 3. We compared these results based on whether the participant was enrolled by an HCP, by a non-HCP, or self-assessment.
Now and future: Strategies for diagnosis, prevention and therapies for Alzheimer's disease.
Sci Bull (Beijing)
December 2024
Department of Neurology, Institute on Aging and Brain Disorders, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China; Neurodegenerative Disorder Research Center, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230026, China. Electronic address:
After a number of failed drug studies on Alzheimer's disease (AD) over the past decade, clinical trials of AD started to show encouraging results and were approved or pending approval for clinical use. However, controversies on the clinically meaningful benefits and risks of brain edema and microhemorrhages have reminded us to think further about monitoring treatment and developing new drug targets. The goal of this review is to find insights from clinical trials that aimed at two key pathological features of AD, i.
View Article and Find Full Text PDFImplementation of the WHO integrated care for older people (ICOPE) programme in clinical practice: a prospective study.
Lancet Healthy Longev
June 2022
Gerontopole, Toulouse University Hospital, WHO Collaborating Center for Frailty, Clinical and Geroscience Research, and Geriatric Training, Toulouse, France; Maintain Aging Research team, Centre d'Epidémiologie et de Recherche en santé des POPulations, Université de Toulouse, Inserm, Université Paul Sabatier, Toulouse, France.
Article Synopsis
- The INSPIRE ICOPE-CARE programme focuses on improving integrated care for older adults by implementing the ICOPE health-care guidelines in real clinical settings.
- A large-scale study was conducted in France, where over 10,000 participants aged 60 and above were screened for intrinsic capacity abnormalities using several digital tools and received training under the WHO ICOPE framework.
- Results showed that 94.3% of participants had positive findings related to their intrinsic health, with a significant follow-up rate of 70.4% after six months, indicating the programme's feasibility and effectiveness in identifying health issues in older adults.